Innovation Pharmaceuticals Inc (IPIX)

[thefamilyman]

Actually the SAEs in Phase 2a were because the patients were being overdosed on Brilacidin. They were giving too much and giving it in a 7 day dosing regimen. The people who designed the Phase 2a trial just did not realize how little of the drug it would take to get the job done.

What we know: B is safer than Dapto (no attributable SAEs -- unlike what ph 2a showed due to poor data followup) and as effective as Dapto across all 3 arms (new info as Big K pointed out). Plus the M-ITT MRSA data is icing on cake. A good CDC resource on MRSA: - slcimmuno